Answers are grounded in this paper and cite their sources.
Cost-effectiveness analysis shows poor cost efficiency of sugemalimab plus chemotherapy in metastatic NSCLC, suggesting pricing and policy adjustments may improve accessibility.
Sugemalimab plus platinum-based chemotherapy offers long-term clinical benefits for metastatic NSCLC but is not cost-effective at current prices in China. Improving cost-effectiveness may require targeting patients with high PD-L1 expression, adjusting reimbursement policies, and reducing drug prices.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: